NCT07076407Phase 3Active not recruiting

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

Study sponsor: Xenon Pharmaceuticals Inc. · XENE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-05Estimated
Enrollment · participants450Estimated
Source updated2026-10-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source